A detailed history of Jpmorgan Chase & CO transactions in Pro Mis Neurosciences Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3 shares of PMN stock, worth $2. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Previous 3 -0.0%
Holding current value
$2
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.5 - $2.49 $375 - $622
-250 Reduced 98.81%
3 $0
Q1 2024

May 10, 2024

SELL
$1.28 - $2.81 $172 - $379
-135 Reduced 34.79%
253 $0
Q3 2023

Nov 14, 2023

SELL
$1.52 - $6.19 $6,852 - $27,904
-4,508 Reduced 92.08%
388 $0
Q2 2023

Aug 11, 2023

SELL
$3.7 - $8.14 $1,110 - $2,442
-300 Reduced 5.77%
4,896 $18,000
Q1 2023

May 11, 2023

SELL
$4.06 - $5.71 $1,217 - $1,713
-300 Reduced 5.46%
5,196 $24,000
Q4 2022

Feb 13, 2023

SELL
$4.33 - $6.29 $9,361 - $13,598
-2,162 Reduced 28.23%
5,496 $25,000
Q3 2022

Nov 14, 2022

BUY
$4.99 - $9.25 $38,213 - $70,836
7,658 New
7,658 $47,000

Others Institutions Holding PMN

About ProMIS Neurosciences Inc.


  • Ticker PMN
  • Exchange OTC
  • Description
  • ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms t...
More about PMN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.